219 related articles for article (PubMed ID: 38292657)
1. Uveal melanoma: Recent advances in immunotherapy.
Sorrentino FS; De Rosa F; Di Terlizzi P; Toneatto G; Gabai A; Finocchio L; Salati C; Spadea L; Zeppieri M
World J Clin Oncol; 2024 Jan; 15(1):23-31. PubMed ID: 38292657
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances and Challenges in Uveal Melanoma Immunotherapy.
Fu Y; Xiao W; Mao Y
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804863
[TBL] [Abstract][Full Text] [Related]
3. Uveal melanoma.
Jager MJ; Shields CL; Cebulla CM; Abdel-Rahman MH; Grossniklaus HE; Stern MH; Carvajal RD; Belfort RN; Jia R; Shields JA; Damato BE
Nat Rev Dis Primers; 2020 Apr; 6(1):24. PubMed ID: 32273508
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment.
Masaoutis C; Kokkali S; Theocharis S
Expert Opin Investig Drugs; 2021 May; 30(5):555-569. PubMed ID: 33650931
[TBL] [Abstract][Full Text] [Related]
5. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.
Livingstone E; Zaremba A; Horn S; Ugurel S; Casalini B; Schlaak M; Hassel JC; Herbst R; Utikal JS; Weide B; Gutzmer R; Meier F; Koelsche C; Hadaschik E; Sucker A; Reis H; Merkelbach-Bruse S; Siewert M; Sahm F; von Deimling A; Cosgarea I; Zimmer L; Schadendorf D; Schilling B; Griewank KG
Br J Dermatol; 2020 Nov; 183(5):928-939. PubMed ID: 32064597
[TBL] [Abstract][Full Text] [Related]
6. Solitary Metastases Presentation from Uveal Melanoma: Report of 3 Cases and a Comprehensive Review of the Literature.
Pereira PM; Luís A; Passos MJ; Gouveia E
Ocul Oncol Pathol; 2023 Feb; 8(4-6):203-210. PubMed ID: 36925729
[TBL] [Abstract][Full Text] [Related]
7. Development of new therapeutic options for the treatment of uveal melanoma.
Wang JZ; Lin V; Toumi E; Wang K; Zhu H; Conway RM; Madigan MC; Murray M; Cherepanoff S; Zhou F; Shu W
FEBS J; 2021 Nov; 288(21):6226-6249. PubMed ID: 33838075
[TBL] [Abstract][Full Text] [Related]
8. Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options.
Brouwer NJ; Verdijk RM; Heegaard S; Marinkovic M; Esmaeli B; Jager MJ
Prog Retin Eye Res; 2022 Jan; 86():100971. PubMed ID: 34015548
[TBL] [Abstract][Full Text] [Related]
9. Liver metastasis in uveal melanoma - treatment options and clinical outcome.
Kaštelan S; Mrazovac Zimak D; Ivanković M; Marković I; Gverović Antunica A
Front Biosci (Landmark Ed); 2022 Feb; 27(2):72. PubMed ID: 35227015
[TBL] [Abstract][Full Text] [Related]
10. Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma.
Mallone F; Sacchetti M; Lambiase A; Moramarco A
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32992823
[TBL] [Abstract][Full Text] [Related]
11. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Uveal Melanoma.
Shoushtari AN; Carvajal RD
Cancer Treat Res; 2016; 167():281-93. PubMed ID: 26601868
[TBL] [Abstract][Full Text] [Related]
13. Driver mutations in
García-Mulero S; Fornelino R; Punta M; Lise S; Varela M; Del Carpio LP; Moreno R; Costa-García M; Rieder D; Trajanoski Z; Gros A; Alemany R; Piulats JM; Sanz-Pamplona R
Oncoimmunology; 2023; 12(1):2261278. PubMed ID: 38126027
[TBL] [Abstract][Full Text] [Related]
14. Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma.
Jindal V
Chin Clin Oncol; 2018 Feb; 7(1):8. PubMed ID: 29486567
[TBL] [Abstract][Full Text] [Related]
15. Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors.
Zhang GM; Huang SS; Ye LX; Liu XL; Shi WH; Ren ZL; Zhou RH; Zhang JJ; Pan JX; Liu SW; Yu L; Li YL
Pharmacol Res; 2022 Oct; 184():106464. PubMed ID: 36162600
[TBL] [Abstract][Full Text] [Related]
16. Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy.
Orloff M
Ocul Oncol Pathol; 2021 Jun; 7(3):168-176. PubMed ID: 34307327
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
[TBL] [Abstract][Full Text] [Related]
18. How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma.
Marseglia M; Amaro A; Solari N; Gangemi R; Croce E; Tanda ET; Spagnolo F; Filaci G; Pfeffer U; Croce M
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922591
[TBL] [Abstract][Full Text] [Related]
19. The genetics of uveal melanoma: current insights.
Helgadottir H; Höiom V
Appl Clin Genet; 2016; 9():147-55. PubMed ID: 27660484
[TBL] [Abstract][Full Text] [Related]
20. Mutations in GNA11 in uveal melanoma.
Van Raamsdonk CD; Griewank KG; Crosby MB; Garrido MC; Vemula S; Wiesner T; Obenauf AC; Wackernagel W; Green G; Bouvier N; Sozen MM; Baimukanova G; Roy R; Heguy A; Dolgalev I; Khanin R; Busam K; Speicher MR; O'Brien J; Bastian BC
N Engl J Med; 2010 Dec; 363(23):2191-9. PubMed ID: 21083380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
